Develop Novel Cancer Drugs

OBI Pharma Inc. (OBI) is dedicated to developing novel cancer therapeutic agents for patients with unmet medical needs. We aim to develop therapeutics that improve patient’s health and quality of life.

Pipeline

ADC

Active Immunotherapy

Targeted Prodrug

BsADC

Technology

ADC Platforms

Enzyme

Our Expertise in Glycoscience

Since 2002, we pioneered our first modality: a glycan antigen-targeted active immunotherapy. Drawing from years of experience in glycoscience, we've elevated our technology to establish OBI’s proprietary glycan-based ADC platforms.

Intellectual Property

+

Patent filed

In US, Europe, Asia, and more

Indication Studied

+

Indications

Broad coverage to unmet medical needs

Worldwide Clinical Studies

+

Sites

Ongoing clinical studies across 13+ countries